Seelos Therapeutics Inc (NASDAQ:SEEL) Risks You Should Know Before Investing

In yesterday’s Wall Street session, Seelos Therapeutics Inc (NASDAQ:SEEL) shares traded at $0.17, up 5.34% from the previous session.

2 analysts cover Seelos Therapeutics Inc (NASDAQ:SEEL), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $4.00, we find $4.00. Given the previous closing price of $0.16, this indicates a potential upside of 2400.0 percent. SEEL stock price is now -59.78% away from the 50-day moving average and -79.16% away from the 200-day moving average. The market capitalization of the company currently stands at $25.94M.

The stock has received a hold rating from 1 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $4.00 as their price target over the next twelve months.

With the price target enhanced from $2.50 to $8, ROTH Capital Upgraded its rating from Neutral to Buy for Seelos Therapeutics Inc (NASDAQ: SEEL).

A total of 2.17% of the company’s stock is owned by insiders.

During the past 12 months, Seelos Therapeutics Inc has had a low of $0.15 and a high of $1.66. The fifty day moving average price for SEEL is $0.4320 and a two-hundred day moving average price translates $0.8329 for the stock.

The latest earnings results from Seelos Therapeutics Inc (NASDAQ: SEEL) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.22, missing analysts’ expectations of -$0.09 by -0.13. This compares to -$0.20 EPS in the same period last year. The net profit margin was -7096.85% and return on equity was -584.20% for SEEL. For the current quarter, analysts expect SEEL to generate $100k in revenue.

Seelos Therapeutics Inc(SEEL) Company Profile

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson’s disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

Related Posts